Suite 1300
Salt Lake City, UT 84111
Block-1 3rd Floor, Perungudi Bypass Rd, Perungudi,
Chennai - 600096
MGR Main Rd,
Perungudi, Chennai - 600096
Villupuram,
Tamil Nadu – 605602
340B Pharmacy Program
340B Pharmacy Compliance and Revenue are at Risk
Split-billing compliance, specialty pharmacy authorization, duplicate discount prevention, and OIG audit readiness — 340B is the highest-value, highest-risk ancillary line in your hospital.
$100B+
Annual 340B drug purchases
program-wide
50%+
Discount on covered outpatient
drugs vs. WAC
Top 3
OIG priority audit target in
hospital compliance
The problem
340B operations are complex and high-risk
Duplicate Discount Violations
340B law prohibits claiming both the 340B discount and the Medicaid drug rebate for the same unit. Inadequate coordination between 340B and Medicaid billing systems is one of the most common — and costly — compliance failures.
Split-Billing Errors
Every drug claim from a 340B-eligible facility must carry the correct modifier (JG or TB). Without a reliable virtual inventory system and rigorous modifier assignment process, billing errors create both overpayment liability and OIG audit exposure.
Contract Pharmacy Misalignment
Manufacturer restrictions on contract pharmacy 340B access have created a fragmented, litigation-driven compliance environment. Keeping billing protocols current with federal court outcomes and HRSA guidance requires ongoing monitoring that most hospital teams cannot sustain alone.
Specialty Drug PA Gaps
340B-eligible drugs are disproportionately specialty medications — biologics, oncology agents, HIV therapies — requiring prior authorization at scale. When PA breaks down before dispensing, both the claim and the 340B eligibility for that dispensation are at risk.
Audit-Readiness Deficits
OIG audits evaluate patient eligibility documentation (encounter with 340B provider within the defined window), drug eligibility (covered outpatient drug), and billing accuracy (correct modifier). Most hospitals cannot demonstrate ongoing documentation integrity across all three dimensions.
Regulatory Environment Volatility
340B is one of the most actively litigated federal healthcare programs. HRSA guidance, federal court rulings, and state-level 340B laws shift frequently, creating a moving compliance target that static internal protocols cannot keep up with.
Key RCM challenges
Split-Billing Compliance
Every drug claim from a 340B-eligible facility must match the correct modifier to the actual drug purchased. This requires a virtual inventory system that tracks 340B purchases at the unit level, with modifier assignment rules that align to each payer's billing requirements. Errors create simultaneous compliance, overpayment, and audit risk.
Contract Pharmacy Complexity
Many 340B covered entities dispense through third-party contract pharmacies. Manufacturer restrictions on contract pharmacy access, federal litigation outcomes, CMS interpretations, and state-level 340B statutes create a compliance environment that requires ongoing monitoring and protocol updates.
Specialty Drug Prior Authorization
A significant proportion of 340B-eligible drugs are specialty medications requiring extensive prior authorization — biologics, oncology agents, HIV medications. Managing PA at scale for these drugs while maintaining 340B eligibility identification throughout the PA process is operationally intensive.
Medicaid Duplicate Discount Prohibition
340B law prohibits claiming both the 340B discount and the Medicaid drug rebate for the same drug unit. Preventing duplicate discounts requires real-time coordination between 340B and Medicaid billing systems — a requirement that is frequently inadequately managed.
OIG Audit Readiness
OIG 340B audits focus on three dimensions: patient eligibility documentation (encounter with a 340B provider within the defined window), drug eligibility (covered outpatient drug status), and billing accuracy (correct modifier on every claim). Maintaining audit-ready documentation across all three is an ongoing compliance obligation.
340B Savings Optimization vs. Compliance Balance
340B success requires balancing financial optimization with strict compliance. Maximizing savings without proper controls dramatically increases audit risk, while overly conservative processes leave substantial program value uncaptured. Sustained performance requires both.
340B Split-Billing Implementation
Workflow design, virtual inventory system integration, modifier assignment rules, and payer-specific billing requirements for 340B drugs. We build the infrastructure that makes compliance sustainable at scale.
340B Billing Compliance Monitoring
Ongoing monitoring of all 340B drug claims for correct JG/TB modifier application, patient eligibility documentation, and drug eligibility verification — with quarterly accuracy reporting and corrective action tracking.
Specialty Pharmacy PA Management
Prior authorization management for 340B-eligible specialty drugs — biologics, oncology agents, HIV medications. PA is secured before dispensing to protect 340B eligibility and prevent non-payment throughout the authorization cycle.
Medicaid Duplicate Discount Prevention
340B-Medicaid billing coordination to prevent duplicate discount violations — including Medicaid carve-out implementation where required by state Medicaid programs. Real-time cross-system flags prevent the most common 340B compliance failure.
Contract Pharmacy Billing Support
Billing support for 340B contract pharmacy dispensing arrangements, including manufacturer restriction compliance, state-specific 340B law alignment, and data reconciliation across multiple pharmacy partners and reporting systems.
OIG Audit Preparation
Full 340B audit readiness assessments covering patient eligibility documentation review, drug claim modifier auditing, and corrective action plan development. Ongoing audit-ready documentation programs for every 340B drug claim.
Key billing & coding highlights
Billing Dimension
Detail & AnnexMed Approach
340B Modifier
JG = drug purchased under 340B; TB = drug not purchased under 340B — required on all applicable drug claims submitted to Medicare and most payers
Applicable Drugs
Covered outpatient drugs dispensed to 340B-eligible patients by covered entity or contract pharmacy within HRSA eligibility parameters
Patient Eligibility
Patient must have a documented encounter with a 340B covered entity provider within the defined time window — encounter documentation is primary audit evidence
Drug Eligibility
Drug must be a covered outpatient drug as defined under 340B statute — not all drugs purchased by a 340B entity qualify; eligibility must be verified at the NDC level
Medicaid Rules
Duplicate discount prohibition applies across fee-for-service and managed care — state MCOs may carve out 340B drugs from managed care contracts; carve-out status must be tracked by payer
Contract Pharmacy
Third-party pharmacy dispensing arrangements subject to manufacturer restrictions and active federal litigation — billing protocols must reflect current court outcomes and HRSA guidance
Split Billing Mechanism
Physical inventory separation or virtual inventory tracking system required — AnnexMed supports virtual inventory integration with hospital pharmacy and billing systems
OIG Audit Priority
340B is a top-3 OIG audit target — patient eligibility, drug eligibility, and billing accuracy reviewed; inadequate documentation = repayment liability and program disenrollment risk
Top Billing Errors
Wrong modifier applied, patient eligibility window lapsed, non-covered drug billed as 340B, Medicaid duplicate discount claimed, contract pharmacy eligibility not confirmed
Revenue Optimization
Maximum 340B savings capture requires comprehensive eligibility identification — undercapturing 340B opportunities is as costly as overbilling; AnnexMed optimizes both dimensions
Medicare Compliance
CMS Final Rule requirements for 340B modifier reporting enforced since 2018 — hospitals must demonstrate system-level compliance with modifier accuracy across all Medicare Part B drug claims
Financial impact
What AnnexMed delivers?
-
18+
Years of experience -
40+
Specialties served -
99.1%
Client retention
25–50%
Drug cost reduction vs. WAC with optimized 340B capture
95%+
340B claim modifier accuracy rate after compliance implementation
100%
Duplicate discount prevention across Medicaid FFS and MCO
Zero
OIG findings goal through ongoing audit-readiness program
Full
Contract pharmacy billing support across all dispensing partners
Disproportionate Share Hospitals
DSH facilities with the highest 340B savings potential and greatest audit exposure
Critical Access Hospitals
CAH facilities leveraging 340B to extend drug access and financial sustainability in rural settings
Cancer Centers & Children's Hospitals
Specialty facilities with high volumes of 340B-eligible oncology and specialty drug dispensing
Contract Pharmacy Networks
Covered entities operating through one or more third-party pharmacy dispensing arrangements
Multi-Site Health Systems
Health systems with multiple covered entities, each requiring distinct 340B compliance protocols and performance tracking
Why AnnexMed for 340B program management?
Split-Billing Compliance Infrastructure
AnnexMed implements 340B split-billing workflows that ensure correct JG/TB modifier assignment on every drug claim — protecting clients from the OIG audit exposure that accompanies even small-scale billing errors at 340B volumes.
Quarterly Compliance Audit Program
Our 340B compliance monitoring includes quarterly billing accuracy audits, patient eligibility sampling, and corrective action reporting — maintaining a state of ongoing audit readiness rather than scrambling when notice arrives.
Integrated Specialty Pharmacy PA Management
We manage specialty pharmacy prior authorization for 340B-eligible drugs as an integrated service — ensuring authorization is secured before dispensing, and 340B eligibility is preserved throughout the PA workflow from request through approval.
Medicaid Carve-Out Coordination
AnnexMed's 340B-Medicaid coordination service prevents duplicate discount violations at the claim level, implementing carve-out protocols where required by state Medicaid programs and tracking MCO-specific 340B policies across all contracted payers.
Contract Pharmacy Regulatory Monitoring
Our team stays current with the rapidly evolving 340B regulatory environment — manufacturer restrictions, federal court rulings, and HRSA guidance updates are monitored continuously and incorporated into client billing protocols as they change.
Revenue & Compliance Balance Expertise
340B is a Compliance Obligation — Not a Revenue Shortcut. We help hospitals maximize legitimate 340B savings while maintaining the documentation integrity and billing accuracy that sustain the program through any audit environment.
Request a 340B Program Assessment
Case Studies
See the impact we deliver
Discover how AnnexMed reduces denials, accelerates reimbursements, and strengthens financial performance. Backed by measurable outcomes and proven RCM expertise, we deliver operational excellence, revenue stability, and sustainable growth you can trust.
Client Voices
See how our clients succeed
Proven RCM expertise. Delivered at scale.
For over 20 years, AnnexMed has delivered RCM solutions nationwide, combining expert billing, coding, and AR support to drive measurable results and growth.
- 20+ years of proven healthcare RCM experience
- 1,500+ professionals supporting billing, coding & AR
- 500+ certified coders across multiple specialties
- 99%+ compliance with HIPAA and security standards
- All 50 states served with consistent, scalable operations
